Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 12Recruiting 5Active not recruiting 4Withdrawn 2Terminated 2

Sponsor Class

OTHER 19INDUSTRY 5NIH 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 2

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Recurrence 1Neoplasms 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × polatuzumab vedotin × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-29

MK-2140-011

Merck Sharp & Dohme LLC

Phase 2 Recruiting
594 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04844866 2026-04-29

DALY 2-EU

Miltenyi Biomedicine GmbH

Phase 2 Recruiting
213 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT04884035 2026-04-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Celgene

Phase 1 Recruiting
224 enrolled
Lymphoid

Lymphoma, B-Cell

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

ADC Therapeutics S.A.

Phase 1 Recruiting
200 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡